Health Catalyst (NASDAQ:HCAT) Given New $6.00 Price Target at Wells Fargo & Company

Health Catalyst (NASDAQ:HCAT) had its price target trimmed by Wells Fargo & Company from $10.00 to $6.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

HCAT has been the topic of several other research reports. Stifel Nicolaus reduced their price target on shares of Health Catalyst from $5.50 to $4.50 and set a “hold” rating on the stock in a report on Friday, August 8th. Evercore ISI reduced their price target on shares of Health Catalyst from $5.00 to $4.00 and set an “in-line” rating on the stock in a report on Wednesday, July 9th. KeyCorp reduced their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, April 16th. Cantor Fitzgerald reissued a “neutral” rating and issued a $4.00 price objective (down previously from $9.00) on shares of Health Catalyst in a research report on Friday, August 8th. Finally, Citigroup lowered shares of Health Catalyst from a “buy” rating to a “neutral” rating and cut their price objective for the company from $6.50 to $3.50 in a research report on Friday, August 8th. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $6.18.

Health Catalyst Stock Up 7.3%

Shares of NASDAQ HCAT opened at $3.22 on Monday. Health Catalyst has a 12-month low of $2.52 and a 12-month high of $9.24. The company has a market capitalization of $226.59 million, a PE ratio of -2.13 and a beta of 1.46. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.24. The firm’s 50-day moving average is $3.79 and its two-hundred day moving average is $4.21.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of the stock. First Light Asset Management LLC increased its position in Health Catalyst by 99.1% during the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company’s stock worth $47,279,000 after purchasing an additional 5,195,686 shares during the last quarter. Daventry Group LP increased its position in Health Catalyst by 3.8% during the fourth quarter. Daventry Group LP now owns 2,509,480 shares of the company’s stock worth $17,742,000 after purchasing an additional 91,878 shares during the last quarter. Nepsis Inc. increased its position in Health Catalyst by 2,072.1% during the first quarter. Nepsis Inc. now owns 2,090,812 shares of the company’s stock worth $9,471,000 after purchasing an additional 1,994,555 shares during the last quarter. Alyeska Investment Group L.P. increased its position in Health Catalyst by 74.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company’s stock worth $14,277,000 after purchasing an additional 861,150 shares during the last quarter. Finally, Primecap Management Co. CA increased its position in Health Catalyst by 3.8% during the first quarter. Primecap Management Co. CA now owns 2,005,116 shares of the company’s stock worth $9,083,000 after purchasing an additional 72,499 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.